Full-Time

Director – Analytical Development

CMC

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Biotechnology

Senior

Cambridge, MA, USA

Requirements
  • BS in a life sciences field, MS or PhD in analytical chemistry with 10+ years of analytical development experience
  • Prior laboratory operations and management experience leading a team of scientists and associates for analytical development in a clinical stage biotech environment
  • Experience with planning and executing product and process development studies such as forced degradation, comparability assessments, stability, etc.
  • Demonstrated competency in operating HPLC/UPLC/LC-MS instrumentation
  • Hands-on experience analyzing DNA/RNA by IP-RP, IEX, LC-fluor and multi-modal LC techniques
  • Direct experience analyzing LNPs and RNA by biophysical techniques such as DSC, CGE, UV thermal analysis, DLS, MALS, Ribogreen, etc.
  • Conceptual understanding of solid phase oligonucleotide synthesis and purification strategies
Responsibilities
  • Lead a team of scientists and research associates working on mRNA, gRNA and LNP assays focused on biophysical methodologies
  • Provide technical expertise for the structural characterization of gRNAs, mRNAs and lipid nanoparticle (LNP) complexes
  • Partner across the Analytical Development team and cross-functionally to lead, plan, and execute complex characterization studies
  • Develop and implement methods intended for a variety of purposes, including release and stability testing, product characterization, and high throughput analysis
  • Serve as analytical lead for CMC project teams
  • Oversee troubleshooting, tech transfer, and phase-appropriate GMP validation of analytical methods
  • Author and review technical reports and regulatory submissions
  • Provide guidance and support to team members, promoting their professional growth and development
  • Effectively manage multiple projects to ensure timely delivery
  • Foster a culture of lab safety, data integrity, collaboration, innovation, continuous improvement and accountability within the team

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Boston, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

5%

1 year growth

14%

2 year growth

70%